Iain McInnes, MD, PhD, University of Glasgow, UK, reviews two papers on tofacitinib. The first paper details outcomes from the STAR-RA study, demonstrating a non-significant increased risk of cardiovascular outcomes among patients with rheumatoid arthritis who have cardiovascular risk factors. The second paper is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching.